Results 141 to 150 of about 390,856 (338)
LP-126 The infectious complication in multitarget therapy of class V lupus nephritis: a case report
Lupus Science and Medicine, 2023 Anastasiia Shumilova +3 more
doaj +1 more source
Mucosal‐Associated Invariant T Cells in Rheumatic Diseases
Arthritis &Rheumatology, EarlyView.Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek +7 more
wiley +1 more source
LP-048 Characteristics and clinical outcome of incomplete systemic lupus erythematosus
Lupus Science and Medicine, 2023 Anastasiia Shumilova +6 more
doaj +1 more source
Arthritis &Rheumatology, EarlyView.Objective This study investigates the role of senescent epidermal basal cells in cutaneous lupus erythematosus (CLE) pathogenesis using skin samples from patients with CLE and a mouse model of systemic lupus erythematosus (SLE). Methods Cellular senescence profiling used datasets from the NCBI GEO database and Accelerating Medicines Partnership (AMP ...
Sena Yamamoto +13 more
wiley +1 more source
Medical geography and its contribution to the aetiology of rare systemic connective tissue diseases : a thesis presented in partial fulfilment of the requirements for the degree of Master of Arts in Geography at Massey University [PDF]
, 1975 This thesis is in two interrelated parts. Part One traced the historical development of medical geography since the idea of applying a geographical perspective to medical problems was first mooted in 4 B.C.
Borman, Graham Barry
core
Arthritis &Rheumatology, EarlyView.Objective Tumornecrosis factor inhibitors (TNFi) have significantly improved rheumatoid arthritis (RA) management, yet variability in patient response remains a substantial challenge, with approximately 40% of patients discontinuing TNFi due to nonresponse or adverse effects.
Chuan Fu Yap +12 more
wiley +1 more source
Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities
Arthritis &Rheumatology, EarlyView.Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley +1 more source